RxDoctor Payments Data

Maly Tiev

Adult Health · Bethpage, NYNPI 1508147398

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (33.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Madrigal Pharmaceuticals at 52.7% of the total. 2025 is the largest year on record at $27,494, more than ten times the $98 reported in 2022. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,883in general payments, 2019–2025

Across 112 payments — averaging $293.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$17K
  • Mirum Pharmaceuticals, Inc.$8K
  • Gilead$4K
  • Ipsen Biopharmaceuticals, Inc$2K
  • AbbVie$381
  • Novo Nordisk$242
  • plus $279 from 5 others

What the payments were for

  • Consulting fees$11,02534%
  • Speaking & faculty fees$11,02534%
  • Travel & lodging$5,68217%
  • Food & beverage$5,15116%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,883 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$30,003
Medicare patients
194
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom67$316,523
VemlidyTenofovir Alafenamide66$89,293
XifaxanRifaximin11$42,873
Ursodiol18$3,651
CholestyramineCholestyramine (With Sugar)16$1,316
Furosemide13$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$17,327$316,52367 claims
GileadVemlidy$4,336$89,29366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →